NCT00351377View on ClinicalTrials.gov

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate

PHASE3CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Autoimmune Disease
Interventions
DRUG

Enteric-coated Mycophenolate Sodium

Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.

Trial Locations (1)

Unknown

Novartis Investigational Site, Various Cities

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY